| Literature DB >> 35462085 |
Michele Carbone1, Harvey I Pass2, Guntulu Ak3, H Richard Alexander4, Paul Baas5, Francine Baumann6, Andrew M Blakely7, Raphael Bueno8, Aleksandra Bzura9, Giuseppe Cardillo10, Jane E Churpek11, Irma Dianzani12, Assunta De Rienzo8, Mitsuru Emi13, Salih Emri14, Emanuela Felley-Bosco15, Dean A Fennell9, Raja M Flores16, Federica Grosso17, Nicholas K Hayward18, Mary Hesdorffer19, Chuong D Hoang20, Peter A Johansson18, Hedy L Kindler21, Muaiad Kittaneh22, Thomas Krausz23, Aaron Mansfield24, Muzaffer Metintas3, Michael Minaai6, Luciano Mutti25, Maartje Nielsen26, Kenneth O'Byrne27, Isabelle Opitz15, Sandra Pastorino6, Francesca Pentimalli28, Marc de Perrot29, Antonia Pritchard30, Robert Taylor Ripley31, Bruce Robinson32, Valerie Rusch33, Emanuela Taioli34, Yasutaka Takinishi6, Mika Tanji6, Anne S Tsao35, A Murat Tuncer36, Sebastian Walpole18, Andrea Wolf37, Haining Yang6, Yoshie Yoshikawa13, Alicia Zolondick6, David S Schrump20, Raffit Hassan38.
Abstract
The most common malignancies that develop in carriers of BAP1 germline mutations include diffuse malignant mesothelioma, uveal and cutaneous melanoma, renal cell carcinoma, and less frequently, breast cancer, several types of skin carcinomas, and other tumor types. Mesotheliomas in these patients are significantly less aggressive, and patients require a multidisciplinary approach that involves genetic counseling, medical genetics, pathology, surgical, medical, and radiation oncology expertise. Some BAP1 carriers have asymptomatic mesothelioma that can be followed by close clinical observation without apparent adverse outcomes: they may survive many years without therapy. Others may grow aggressively but very often respond to therapy. Detecting BAP1 germline mutations has, therefore, substantial medical, social, and economic impact. Close monitoring of these patients and their relatives is expected to result in prolonged life expectancy, improved quality of life, and being cost-effective. The co-authors of this paper are those who have published the vast majority of cases of mesothelioma occurring in patients carrying inactivating germline BAP1 mutations and who have studied the families affected by the BAP1 cancer syndrome for many years. This paper reports our experience. It is intended to be a source of information for all physicians who care for patients carrying germline BAP1 mutations. We discuss the clinical presentation, diagnostic and treatment challenges, and our recommendations of how to best care for these patients and their family members, including the potential economic and psychosocial impact.Entities:
Keywords: Asbestos; BAP1; Cancer genetics; Germline mutations; Mesothelioma; Tumor predisposition syndromes
Mesh:
Substances:
Year: 2022 PMID: 35462085 PMCID: PMC9233126 DOI: 10.1016/j.jtho.2022.03.014
Source DB: PubMed Journal: J Thorac Oncol ISSN: 1556-0864 Impact factor: 20.121